MAP2K7 and glioma: In our cohort, all five NF1 patients with molecular low-grade gliomas that were treated with small molecule MEK inhibitors (either selumetinib or trametinib) experienced stable disease or tumor regression and did not require additional therapies, whereas patients with molecular high-grade gliomas did not respond to single agent MEK inhibition.